Evidence
Front Psychiatry. 2023 May 4;14:1176266. doi: 10.3389/fpsyt.2023.1176266. eCollection 2023.
ABSTRACT
INTRODUCTION: Neurofilament light chain protein (NfL) is a fluid biomarker of neural injury measurable in cerebrospinal fluid and blood. Patients with different neurodegenerative disorders and mild traumatic brain injury display elevated levels of NfL. However, so far, elevated levels of NfL have not been demonstrated in persons with psychiatric disorders. To our knowledge, the occurrence of NfL in the blood has not previously been studied in persons undergoing forensic psychiatric assessment or persons treated in forensic mental health services. Supposedly, these persons suffer from experiences and conditions with a higher risk of neural injury than other psychiatric patients.
METHODS: In this pilot study, we investigated plasma levels of NfL in 20 persons undergoing forensic psychiatric assessment and 20 patients at a forensic psychiatric hospital. NfL values were compared with control groups of healthy individuals matched for age and sex.
RESULTS: The prevalence of increased NfL in both forensic groups was low and did not differ compared with the controls. However, some persons undergoing forensic psychiatric assessment showed slightly elevated values.
DISCUSSION: The slightly elevated values were observed in the group investigated closer in time to the index crime, when elevated NfL levels could be expected to be more prevalent due to acute conditions from the time of the offense. This gives reason to look further into this group.
PMID:37215673 | PMC:PMC10192562 | DOI:10.3389/fpsyt.2023.1176266
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Plasma neurofilament light chain protein is not increased in forensic psychiatric populations: a pilot study
🌐 90 Days
VR Related Evidence Matrix
- Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls
- Plasma neurofilament light chain is not elevated in people with first-episode psychosis or those at ultra-high risk for psychosis
- Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk
- Cluster analysis dissecting cognitive deficits in older adults with major depressive disorder and the association with neurofilament light chain
- Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy
- Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
- Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome
- Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and Early Diabetic Polyneuropathy: ADDITION-Denmark
- NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease
- Brain injury plasma biomarkers in patients on veno-arterial extracorporeal membrane oxygenation: A pilot prospective observational study
- Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men
- Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
- Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
- Diagnostic markers of acute encephalitis syndrome and COVID-associated multisystem inflammatory syndrome in children from Southern India
- Sleep and APOE-ε4 have a synergistic effect on plasma biomarkers and longitudinal cognitive decline in older adults
- Evolution of brain injury and neurological dysfunction after cardiac arrest in the rat - A multimodal and comprehensive model
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study
- Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
- Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
- Neurofilament light chain is elevated in patients with newly diagnosed idiopathic intracranial hypertension: A prospective study
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly
- Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer's disease
- Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population
- Racial discrimination during middle age predicts higher serum phosphorylated tau and neurofilament light chain levels a decade later: A study of aging black Americans
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Biochemical, Biomarker, and Behavioral Characterization of the GrnR493X Mouse Model of Frontotemporal Dementia
- Plasma glial fibrillary acidic protein and tau: predictors of neurological outcome after cardiac arrest
- Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort
- Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
- Fluid biomarkers of the neurovascular unit in cerebrovascular disease and vascular cognitive disorders: A systematic review and meta-analysis
- Forensic Aftercare Facilities and Their Impact on the Releasability of Persons Who Committed Sexual Offenses: A Three Group Comparison
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients
- Biomarkers of Neurodegeneration and Alzheimer's Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study
- Repetitive head injuries in German American football players do not change blood-based biomarker candidates for CTE during a single season
- Post-discharge pharmacological treatment discontinuation of forensic psychiatric patients in Sweden
- Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies
- New knowledge on anti-IgLON5 disease
- Monitoring Persons' Rights to Equal Care: Registered nurses' Experiences of Caring for People with Mental Ill-Health and Somatic Comorbidity in Psychiatric Outpatient Care
- Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis
- Neuroimaging and plasma evidence of early white matter loss in Parkinson's disease with poor outcomes
- Epidemiology and prevalence of dementia and Alzheimer's disease in American Indians: Data from the Strong Heart Study
- Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits
- Characteristics of forensic psychiatric patients with a neurocognitive disorder
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- IgG and kappa free light chain CSF/serum indices: evaluating intrathecal immunoglobulin production in HIV infection in comparison with multiple sclerosis
- Are Advanced Oxidation Protein Products (AOPPs) Levels Altered in Neuropsychiatric Disorders? An Integrative Review
- Homeless people: a review of personality disorders
- Homeless people: a review of personality disorders
- Staff supported community outings among forensic mental health patients: patient characteristics, rehabilitative goals, and (the absence of) adverse outcomes
- Identity and Personality Pathology in Adult Forensic Psychiatric Patients and Healthy Controls
- Identity and Personality Pathology in Adult Forensic Psychiatric Patients and Healthy Controls
- Clinical Characteristics of Asymptomatic Thromboembolism in Psychiatric Inpatients: A Retrospective Study
- Gender-affirming treatment and mental health diagnoses in Danish transgender persons: a nationwide register-based cohort study
- Depression in Persons With Epilepsy: Lessons From Case Review
- Depression in Persons With Epilepsy: Lessons From Case Review
- A pilot study examining hemomania behaviors in psychiatry outpatients engaged with nonsuicidal self-injury
- Elusive cases in forensic psychiatry? Exploring subgroups of schizophrenia spectrum disorder patients in Germany
- Criminological and Psychiatric Profiles of Immigrant and Refugee Offenders: A Retrospective Analysis of Cases in a Forensic Setting
- Distribution of quetiapine between serum and whole blood in therapeutic drug monitoring specimens
- Risk and protective factors in risk assessment: Predicting inpatient aggression in adult males detained in a forensic mental health setting
- The burden for clinical services of persons with an intellectual disability or mental disorder convicted of criminal offences: A birth cohort study of 14,605 persons followed to age 64
- Ethics and law in the application of new technology in forensic psychiatry
Evidence Blueprint
Plasma neurofilament light chain protein is not increased in forensic psychiatric populations: a pilot study
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Plasma neurofilament light chain protein is not increased in forensic psychiatric populations: a pilot study
🌐 365 Days
VR Related Evidence Matrix
- Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls
- Plasma neurofilament light chain is not elevated in people with first-episode psychosis or those at ultra-high risk for psychosis
- Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
- Plasma and cerebrospinal fluid concentrations of neurofilament light protein correlate in patients with idiopathic normal pressure hydrocephalus
- Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk
- Neurofilament Light Chain: A Translational Safety Biomarker for Drug-Induced Peripheral Neurotoxicity
- Changes of neurofilament light chain in patients with alcohol dependence following withdrawal and the genetic effect from ALDH2 Polymorphism
- Cluster analysis dissecting cognitive deficits in older adults with major depressive disorder and the association with neurofilament light chain
- Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury
- Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy
- Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
- Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges
- Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome
- Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and Early Diabetic Polyneuropathy: ADDITION-Denmark
- NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease
- Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice
- Hypotension during transsphenoidal pituitary surgery associated with increase in plasma levels of brain injury markers
- Neurofilament light chain levels in serum among a large mixed memory clinic cohort: Confounders and diagnostic usefulness
- Brain injury plasma biomarkers in patients on veno-arterial extracorporeal membrane oxygenation: A pilot prospective observational study
- Head Kinematics, Blood Biomarkers and Histology in Large Animal Models of Traumatic Brain Injury and Hemorrhagic Shock
- Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men
- NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study
- Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
- Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
- Diagnostic markers of acute encephalitis syndrome and COVID-associated multisystem inflammatory syndrome in children from Southern India
- The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: the Shanghai Aging Study
- Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study
- Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
- Serum neurofilament light chain in COVID-19 and the influence of renal function
- Association of Neurofilament Light Chain, [18F]PI-2620 Tau-PET, TSPO-PET, and Clinical Progression in Patients With β-Amyloid-Negative CBS
- Sleep and APOE-ε4 have a synergistic effect on plasma biomarkers and longitudinal cognitive decline in older adults
- Evolution of brain injury and neurological dysfunction after cardiac arrest in the rat - A multimodal and comprehensive model
- Impact of demographics and comorbid conditions on plasma biomarkers concentrations and their diagnostic accuracy in a memory clinic cohort
- Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: The cardiovascular health study
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study
- Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
- Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
- Neurofilament light chain is elevated in patients with newly diagnosed idiopathic intracranial hypertension: A prospective study
- Neurological involvement among non-hospitalized adolescents and young adults 6 months after acute COVID-19
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly
- Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer's disease
- Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population
- Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19
- The presence of preoperative neurodegeneration biofluid markers in patients with postoperative delirium
- Ketone bodies mediate alterations in brain energy metabolism and biomarkers of Alzheimer's disease
- Cortical thickness modeling and variability in Alzheimer's disease and frontotemporal dementia
- A peripheral signature of Alzheimer's disease featuring microbiota-gut-brain axis markers
- Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study
- Racial discrimination during middle age predicts higher serum phosphorylated tau and neurofilament light chain levels a decade later: A study of aging black Americans
- Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson's disease patients
- Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease
- Investigating neural dysfunction with abnormal protein deposition in Alzheimer's disease through magnetic resonance spectroscopic imaging, plasma biomarkers, and positron emission tomography
- Brain magnetic resonance imaging findings six months after critical COVID-19: A prospective cohort study
- Septic encephalopathy in the elderly - biomarkers of potential clinical utility
- Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms
- Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease
- Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings
- Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression
- Association between plasma CTRPs with cognitive impairment and neurodegeneration of Alzheimer's disease
- Nano-Brush Structure for Rapid Label-Free Differentiation of Alzheimer's Disease Stages and Direct Capture of Neuron-Derived Exosomes from Human Blood Plasma
- Association of Serum Brain-Derived Tau With Clinical Outcome and Longitudinal Change in Patients With Severe Traumatic Brain Injury
- Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial